Fidelity Investments
OREX

Fidelity Investments’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Fidelity Investments’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-741,276
Closed -$4.17M – 2777
2016
Q1 		$4.17M Sell
741,276
-418,595
-36% -$5.44M ﹤0.01% 2209
2015
Q4 		$19.9M Hold
1,159,871
– – ﹤0.01% 1696
2015
Q3 		$24.5M Hold
1,159,871
– – ﹤0.01% 1577
2015
Q2 		$57.4M Buy
1,159,871
+70,450
+6% +$4.21M 0.01% 1280
2015
Q1 		$85.3M Buy
1,089,421
+28,023
+3% +$1.74M 0.01% 1095
2014
Q4 		$64.3M Buy
1,061,398
+48,310
+5% +$2.43M 0.01% 1213
2014
Q3 		$43.2M Buy
1,013,088
+20,930
+2% +$1.12M 0.01% 1362
2014
Q2 		$61.3M Buy
992,158
+300,970
+44% +$17.5M 0.01% 1258
2014
Q1 		$44.9M Buy
691,188
+382,433
+124% +$25.9M 0.01% 1380
2013
Q4 		$17.4M Sell
308,755
-236,240
-43% -$13.3M ﹤0.01% 1768
2013
Q3 		$33.5M Buy
544,995
+183,590
+51% +$12.4M 0.01% 1464
2013
Q2 		$21.1M Buy
+361,405
New +$22.2M ﹤0.01% 1644

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments's OREX Position: Q2 2016 in Review

Fidelity Investments sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 741,276 shares — an estimated $4.17M sold.

Fidelity Investments first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $85.3M in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Fidelity Investments reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Fidelity Investments sold 741,276 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $4.17M.
  • Fidelity Investments first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • Fidelity Investments's Orexigen Therapeutics, Inc. position peaked at $85.3M in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Fidelity Investments's 13F filing for Q2 2016, filed 11 Aug 2016.